Oslo, Norway, November 23, 2021 - Vaccibody AS, a clinical-stage
biopharmaceutical company dedicated to the discovery and development of vaccines
and novel immunotherapies, hereby calls for an Extraordinary General Meeting
(EGM) to be held at meeting room Toppsenteret - FAROS - Building H - Floor 5 in
Gaustadalléen 21, Oslo, Norway at 10:00 CET on November 30, 2021. 

The notice of the EGM is attached. All documents regarding the EGM are also
available at the Company's website: www.nykode.com/media/news-and-announcements.

The following items are on the agenda: (i) Change of the company's name to
Nykode Therapeutics AS, (ii) Extension of expiry date for warrants and (iii)
Election of members to the Nomination Committee. 

Shareholders representing 44.40 % of the outstanding shares have already
undertaken to vote in favor of the items on the agenda. 

Due to the ongoing corona virus pandemic, the Board encourages shareholders not
to attend the general meeting in person, but rather to make use of the ability
to vote by proxy. The proxy form will be found at the above weblink.

For further information, please see the Company's website or contact CFO Harald
Gurvin. Please see below for contact details. 


About Nykode Therapeutics*)

Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment cancer and infectious diseases. Nykode Therapeutics' modular vaccine
technology specifically targets antigens to Antigen Presenting Cells, which are
essential for inducing rapid, strong and long-lasting antigen specific immune
responses and elicit efficacious clinical responses. 

Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment
of human papilloma virus 16 induced malignancies which is in Phase 2 for the
treatment of cervical cancer